title: Arzoxifene Eli Lilly.
abstract: Arzoxifene is a benzothiophene second-generation selective estrogen receptor modulator (SERM) under development by Eli Lilly & Co as a potential treatment for cancer.
authors.affiliation: University of California, Davis, Department of Internal Medicine, Division of Hematology/Oncology, 4501 X Street Room 3016, Sacramento, CA 95817, USA. mwdegregorio@ucdavis.edu
authors.forename: Cristina
authors.initials: C
authors.lastname: Marchisano-Karpman
authors.forename: Micheal W
authors.initials: MW
authors.lastname: DeGregorio
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D010880:Piperidines / Q000737:chemistry / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000379:methods*; D013876:Thiophenes / Q000737:chemistry / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D010880:Piperidines; D013876:Thiophenes; C115121:LY 353381